Twenty-five years in the making: flecainide is safe and effective for the management of atrial fibrillation
about
2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society.Quality of care in patients with atrial fibrillation in primary care: a cross-sectional study comparing clinical and claims data.The Role of Flecainide in the Management of Catecholaminergic Polymorphic Ventricular Tachycardia.Intermittent failure to capture: What is the mechanism?Flecainide and elevated liver enzymes in α1-antitrypsin deficiencyNovel pharmacological targets for the rhythm control management of atrial fibrillation.Narrow therapeutic index drugs: a clinical pharmacological consideration to flecainide.Flecainide in Amyotrophic Lateral Sclerosis as a Neuroprotective Strategy (FANS): A Randomized Placebo-Controlled Trial.Amiodarone and risk of death in contemporary patients with atrial fibrillation: Findings from The Retrospective Evaluation and Assessment of Therapies in AF study.The evolving landscape of oral anti-arrhythmic prescriptions for atrial fibrillation in England: 1998-2014.Antiarrhythmic and electrophysiologic effects of flecainide on acutely induced atrial fibrillation in healthy horses.Brugada pattern masquerading as ST-segment elevation myocardial infarction in flecainide toxicitySafety of flecainide.Flecainide acetate for the treatment of atrial and ventricular arrhythmias.Safety and efficacy of vernakalant for acute cardioversion of atrial fibrillation: an update.The efficacy and tolerability of commonly used agents to prevent recurrence of atrial fibrillation after successful cardioversion.Mechanisms underlying atrial-selective block of sodium channels by Wenxin Keli: Experimental and theoretical analysis.New antiarrhythmic targets in atrial fibrillation.Novel therapies in development that inhibit motor neuron hyperexcitability in amyotrophic lateral sclerosis.Broad, broader, broadest.Cardiac devices with class 1C antiarrhythmics: a potentially toxic combinationParoxysmal atrial fibrillation recurrences and quality of life in symptomatic patients: A crossover study of flecainide and pilsicainide.An infrared optical pacing system for screening cardiac electrophysiology in human cardiomyocytes.Flecainide ameliorates arrhythmogenicity through NCX flux in Andersen-Tawil syndrome-iPS cell-derived cardiomyocytes.The novel late Na+ current inhibitor, GS-6615 (eleclazine) and its anti-arrhythmic effects in rabbit isolated heart preparationsMolecular basis of hERG potassium channel blockade by the class Ic antiarrhythmic flecainide.[Antiarrhythmic agents].Combination drug therapy for patients with intractable ventricular tachycardia associated with right ventricular cardiomyopathy.Have the Findings from Clinical Risk Prediction and Trials Any Key Messages for Safety Pharmacology?Flecainide-metoprolol combination reduces atrial fibrillation clinical recurrences and improves tolerability at 1-year follow-up in persistent symptomatic atrial fibrillation.Cardiac computed tomography in patients with symptomatic new-onset atrial fibrillation, rule-out acute coronary syndrome, but with intermediate pretest probability for coronary artery disease admitted to a chest pain unit.Coronary Artery Calcium as an Independent Surrogate Marker in the Risk Assessment of Patients With Atrial Fibrillation and an Intermediate Pretest Likelihood for Coronary Artery Disease Admitted to a German Chest Pain Unit.An unusual case of flecainide-induced QT prolongation leading to cardiac arrest.Flecainide toxicity in renal failure.Atrial fibrillationSlow Recovery of Excitability Increases Ventricular Fibrillation Risk as Identified by EmulationTime-dependent antiarrhythmic effects of flecainide on induced atrial fibrillation in horsesOn-chip spatiotemporal electrophysiological analysis of human stem cell derived cardiomyocytes enables quantitative assessment of proarrhythmia in drug development
P2860
Q27341873-233CE3EF-0F9C-414F-9886-810A97A85898Q31149219-C7D6B79D-6A32-4D9D-A843-9797CCBFD43CQ33167418-448AD81F-12FC-4512-B479-8E71C9C080A8Q33625455-5DCD5A03-C6FE-44D5-B7C9-0499897F7F29Q33643591-B419E3CF-CCE0-4185-AFBB-E0D1D548ECE5Q35489060-0F184D6E-E8D1-4FDD-B188-74CA86035F72Q35547234-01901645-B09E-4B4F-87A0-D4C50A2F170CQ36437641-9AF98A20-0278-4ABA-9430-34FB9241E60BQ36709675-C739BDC4-0456-4C3E-8D8F-5717B45F5F70Q36860614-95D63180-1EFF-4D39-BC5F-CE47079A00F9Q36873774-CFE0073E-3B7D-4C58-A791-668828F00B79Q37388192-618131BB-DA00-4604-9A8C-D5281F78F38BQ37995638-59FEDBBB-97BF-4DFC-9E77-3A7BCB4B3D12Q38072091-32770892-3FB1-43E8-85B4-F43121C40B22Q38103541-8566A9B0-EB85-4C0E-A992-6187669FAE48Q38194112-84354E9D-B1C1-40D4-B084-292F4B906C5CQ38548311-05DE0054-F864-4C99-8779-64FF8E77B686Q38648539-237FC094-FA0B-4BFE-A79A-50A5214DD3FFQ38868221-E003E974-AFFB-42DD-8BF3-BBB4B8E589FDQ39952671-D4738F4A-178A-419C-9C51-A7F930307B1BQ41045131-07DE6CE6-912F-4939-B353-B85F3350808CQ41141383-9E575328-717D-4F08-8368-2A27404F5D7FQ41512444-1B6C3B17-53B0-4DC8-806D-8F385AD5DCD2Q41682376-8BE7B462-169D-4256-B339-FD0578880151Q42682285-ED035006-1B97-4331-A22A-B891AFC260A7Q43070404-2642CC36-3FD9-48FF-8FED-8DE609A1B06CQ44907209-496A46EF-8C07-4015-9047-4C8D0D045B4DQ45976989-7E8D89C4-FB4A-40DC-ABD7-697724B7DE3FQ46607609-DA761A1B-1702-4B80-9DA2-9D767A4FFC9FQ47628139-E4419A7D-890E-4B85-AA19-0AAD7E56D9CBQ49332853-AACC24EE-D810-4ABA-923F-C7D36E0751B9Q52984202-7320B0C9-3A9E-422A-86FF-90F4A1363B0EQ53623654-E725939C-295C-4D4D-81C7-9D4E4C42B6EBQ55345141-A1087C61-B72A-4E9F-967A-E1C4654E0CA4Q56607936-26E3E176-8CEE-43E6-9822-7A5B35DF67C2Q58698119-62B70C80-9A74-4696-8BA2-A73F83F51B25Q58716724-CB82B0DC-9EFC-43A1-8275-F95A62B6EB37Q59126210-E37DB9CC-6FC4-4F58-8B02-5BD2B7B953E4
P2860
Twenty-five years in the making: flecainide is safe and effective for the management of atrial fibrillation
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Twenty-five years in the makin ...... agement of atrial fibrillation
@ast
Twenty-five years in the makin ...... agement of atrial fibrillation
@en
Twenty-five years in the makin ...... agement of atrial fibrillation
@nl
type
label
Twenty-five years in the makin ...... agement of atrial fibrillation
@ast
Twenty-five years in the makin ...... agement of atrial fibrillation
@en
Twenty-five years in the makin ...... agement of atrial fibrillation
@nl
prefLabel
Twenty-five years in the makin ...... agement of atrial fibrillation
@ast
Twenty-five years in the makin ...... agement of atrial fibrillation
@en
Twenty-five years in the makin ...... agement of atrial fibrillation
@nl
P2093
P2860
P356
P1433
P1476
Twenty-five years in the makin ...... agement of atrial fibrillation
@en
P2093
Alessandro Capucci
Andreas Goette
Etienne Aliot
Harry J Crijns
P275
P2860
P304
P356
10.1093/EUROPACE/EUQ382
P50
P5008
P577
2010-12-07T00:00:00Z
2011-02-01T00:00:00Z